QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW

QRG Capital Management Inc. lifted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,464 shares of the medical research company's stock after acquiring an additional 18,172 shares during the period. QRG Capital Management Inc.'s holdings in Edwards Lifesciences were worth $4,643,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after buying an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $238,688,000. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company's stock worth $161,055,000 after purchasing an additional 1,111,139 shares during the period. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Up 0.4%

EW stock opened at $83.21 on Thursday. The business has a fifty day moving average price of $82.15 and a 200 day moving average price of $82.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $87.89. The stock has a market capitalization of $47.97 billion, a price-to-earnings ratio of 44.26, a P/E/G ratio of 2.08 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. During the same quarter in the prior year, the business earned $0.64 earnings per share. The business's revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on EW. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an "outperform" rating in a research note on Monday, April 13th. BTIG Research raised their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday, April 24th. Finally, Barclays reiterated an "overweight" rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $95.65.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the firm's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the completion of the sale, the vice president owned 33,682 shares of the company's stock, valued at $2,828,614.36. This trade represents a 2.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company's stock, valued at $3,177,507.96. This trade represents a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 88,096 shares of company stock worth $7,288,799. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.